Ursodeoxycholic Acid Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The Ursodeoxycholic Acid market centers on a bile-acid derivative used as the standard first-line pharmacotherapy for cholestatic liver diseases, most notably primary biliary cholangitis, and increasingly evaluated in metabolic liver conditions such as MASLD and MASH. With a 2025 valuation near USD 1.2 billion and projected growth of roughly 7.5% annually, the market is being lifted by expanding patient populations and steady clinical adoption. Its position as the foundational therapy in PBC treatment pathways anchors continued volume demand even as newer agents enter the field.

• •Global valuation around USD 1.2 billion in 2025 with ~7.5% CAGR.
• •UDCA is the universally recommended first-line therapy for primary biliary cholangitis.
• •Demand extends into metabolic liver disease indications including MASLD and MASH.

Rising prevalence of metabolic liver disease linked to type 2 diabetes is expanding the eligible patient base for bile-acid therapies through 2030 and beyond. Regulatory approvals of new agents intended for use in combination with UDCA are reinforcing its central role rather than displacing it, sustaining prescription volumes. Formulation innovation, including microencapsulated and multiparticulate delivery systems, is also broadening clinical utility and supporting pricing in differentiated product segments.

• •Epidemiological growth in MASLD/MASH tied to metabolic disease is enlarging demand.
• •Recent approvals of second-line agents used alongside UDCA preserve its first-line position.
• •Advanced delivery formats such as microspheres and micropellets add differentiated value.

The market is segmented by indication (PBC as the core, with growing off-label and investigational use in cholestatic and metabolic liver disease), formulation (conventional oral tablets/capsules and advanced multiparticulates), and end-user setting. Europe represents a mature, high-volume region given longstanding PBC diagnosis pathways and institutional frameworks supporting liver health implementation. Asia-Pacific is exhibiting above-average expansion on the back of improving diagnostic infrastructure and rising metabolic disease burden, while North America contributes significant revenue through established specialty care channels.

• •PBC remains the core indication, with MASLD/MASH as a growing adjacent segment.
• •Europe is the most mature regional market due to established cholestatic liver disease care.
• •Asia-Pacific shows above-average growth on rising diagnosis rates and metabolic disease prevalence.

What are the recent trends and outlook?

Through 2030, the market outlook is shaped by the dual trends of growing patient demand from metabolic liver disease and a competitive environment enriched by combination regimens. Real-world evidence documenting UDCA response rates in PBC is informing treatment algorithms and supporting earlier initiation, which sustains volume growth. Pricing models and reimbursement structures vary across regions, with European institutions documenting sustainable access frameworks that may serve as templates elsewhere.

• •Patient pool is projected to expand through 2030 on rising metabolic liver disease prevalence.
• •Real-world UDCA response data is reinforcing earlier, broader first-line use in PBC.
• •Regional access and pricing models are diverging, influencing uptake trajectories.